Novo Nordisk launched oral Wegovy in the U.S. while Medicare set co-pays for the bridge program, alongside soaring sales for Eli Lilly's drugs.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novo Nordisk launched oral Wegovy in the U.S. while Medicare set co-pays for the bridge program, alongside soaring sales for Eli Lilly's drugs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
-
Eli Lilly and Company
American pharmaceutical company
-
Medicare
US federal health insurance
Related events
- Novo Nordisk and Astellas Pharma are noted as large-cap healthcare companies, with Novo Nordisk reporting higher revenue and earnings.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.